八正化石胶囊联合坦洛新片治疗输尿管结石患者的疗效及对sVCAM-1、IGFBP7表达的影响  

Clinical efficacy of Bazheng Huashi Capsule combined with tanloxin tablet in the treatment of ureteral calculi and its effect on the expression of sVCAM-1 and IGFBP7

作　　者：金炳岑 周广军[1] 郑志华 史晓熠 冯娜娜[4] JIN Bing-cen;ZHOU Guang-jun;ZHENG Zhi-hua(Department of Urology,Cangzhou Hospital Of Integrated TCM-WM Hebei,Cangzhou Hebei 061001,China;Department of Laboratory Diagnosis,Cangzhou Hospital Of Integrated TCM-WM Hebei,Cangzhou Hebei 061001,China)

机构地区：[1]河北省沧州中西医结合医院泌尿外科,河北沧州061001 [2]河北省沧州中西医结合医院实验诊断科,河北沧州061001 [3]河北省沧州中西医结合医院胸外科,河北沧州061001 [4]河北省沧州中西医结合医院科教部,河北沧州061001

出　　处：《临床和实验医学杂志》2022年第23期2525-2529,共5页Journal of Clinical and Experimental Medicine

基　　金：河北省中医药管理局科研计划项目(编号:2020489)。

摘　　要：目的探究八正化石胶囊联合坦洛新片治疗输尿管结石患者的疗效及对可溶性血管细胞黏附分子-1(sVCAM-1)、胰岛素样生长因子结合蛋白7(IGFBP7)表达的影响。方法前瞻性选取2021年1月至12月河北省沧州中西医结合医院收治入院的90例有输尿管结石症状的患者进行研究,按照简单随机化法分为对照组、治疗组,各45例。对照组采用坦洛新片治疗,0.2 mg/次,1次/d,共治疗2周,治疗组在对照组基础上八正化石胶囊治疗,8粒/次,3次/d,共治疗2周。检测并比较两组一般相关指标、血清炎症因子[超敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]、sVCAM-1、IGFBP7、临床疗效、不良反应。结果治疗组结石排净时间、结石排净率、血尿持续时间、抗生素使用率、抗生素使用天数、肾绞痛发生率、镇痛药使用率、镇痛药使用剂量、视觉模拟评分法(VAS)评分、第2次碎石率均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组hs-CRP、IL-6、TNF-α、sVCAM-1、IGFBP7水平均较治疗前降低,且治疗组hs-CRP、IL-6、TNF-α、sVCAM-1、IGFBP7水平为(3.26±0.32)mg/L、(2.06±0.13)ng/L、(31.51±5.37)ng/L、(210.29±32.76)ng/mL、(16.83±4.71)ng/mL,均低于对照组[(6.23±1.57)mg/L、(4.92±0.69)ng/L、(41.37±10.27)ng/L、(653.79±86.51)ng/mL、(81.27±16.53)ng/mL],差异均有统计学意义(P<0.05)。治疗组临床疗效总有效率为97.78%,高于对照组(82.22%),差异有统计学意义(P<0.05)。治疗组患者不良反应发生率为4.44%,低于对照组(20.00%),差异有统计学意义(P<0.05)。结论采用八正化石胶囊、坦洛新片联合治疗输尿管结石患者可提高临床疗效,改善患者临床症状,并有效降低炎症因子和sVCAM-1、IGFBP7表达水平。Objective To explore the clinical efficacy of Bazheng Huashi Capsule combined with tanloxin tablet in the treatment of ureteral calculi and its effect on the expression of soluble vascular cell adhesionmolecules-1(sVCAM-1)and insulin-like growth factor binding protein 7(IGFBP7)in patients with ureteric stones.Methods The 90 patients with ureteral calculi admitted to Cangzhou Hospital Of Integrated TCM-WM Hebei from January to December 2021 were selected for prospective study and divided into the control group and 45 patients in the treatment group according to the simple randomization.The control group was treated with tamsulosin,0.2 mg/time,once a day,for a total of 2 weeks.The treatment group was treated with Bazheng Fossil Capsule,8 capsules/time,three times a day,on the basis of the control group,for a total of 2 weeks.General related indexes,serum inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],SVCAM-1,IGFBP7,clinical efficacy and adverse reactions were detected and compared.Results The stone clearance time,stone clearance rate,hematuria duration,antibiotic use rate,antibiotic use days,incidence of renal colic,analgesic use rate,analgesic use dose,visual analogue scale(VAS)score,the second crushed stone rate of the treatment group were lower than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of hs CRP,IL-6,TNF-α,sVCAM-1 and IGFBP7 were lower than those before treatment,and the levels of hs-CRP,IL-6,TNF-α,sVCAM-1 and IGFBP7 in the treatment group were(3.26±0.32)mg/L,(2.06±0.13)ng/L,(31.51±5.37)ng/L,(210.29±32.76)ng/mL,(16.83±4.71)ng/mL,which were lower than those in the control group[(6.23±1.57)mg/L,(4.92±0.69)ng/L,(41.37±10.27)ng/L,(653.79±86.51)ng/mL,(81.27±16.53)ng/mL],and the differences were statistically significant(P<0.05).The total effective rate of the treatment group was 97.78%,which was higher than that of the control group(82.22%),and the difference

关 键 词：输尿管结石 八正化石胶囊 坦洛新片 胰岛素样生长因子结合蛋白7 可溶性血管细胞黏附分子-1 

分 类 号：R693.4[医药卫生—泌尿科学]